Aptevo Therapeutics Inc.: CVI Investments, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
CVI Investments, Inc. filed an amended Schedule 13G with the SEC disclosing a change to its ownership stake in Aptevo Therapeutics Inc., per accession number 0001649553-26-000140. The filing updates the investor's previously reported position in the clinical-stage biotech, though the amended disclosure did not specify a revised share count or percentage in the headline details. Schedule 13G amendments are typically filed by passive investors when their beneficial ownership crosses or moves within the 5% reporting threshold, making the update a signal of shifting institutional interest in the small-cap company. Aptevo, which develops novel cancer immunotherapies, remains closely watched by investors for pipeline and financing developments. What to watch next: the specific share totals and ownership percentage in the amended filing, and any further 13G or 13D activity that could indicate a more active stance by CVI or other holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aptevo Therapeutics Inc., CVI Investments, Inc.